Testing a polygenic risk score for morphological microglial activation in Alzheimer's disease and aging

Earvin S Tio1,2, Timothy J Hohman3, Milos Milic1

  • 1Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON, CANADA.

Insights

A new polygenic risk score (PRS) for microglial activation did not improve prediction of Alzheimer's disease (AD) diagnosis or cognitive decline. Further research requires larger genome-wide studies of neuroinflammation for better PRS development.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Neuroinflammation and microglial activation are early events in Alzheimer's disease (AD).
  • Direct in-vivo observation of microglia is currently not feasible.
  • Polygenic risk scores (PRS) offer a way to index heritable predispositions.

Conclusions:

  • A PRS derived from microglial activation markers does not currently enhance AD risk prediction.
  • Larger, well-powered genome-wide studies of microglial activation are needed for improved PRS development.
  • Future biobank studies should incorporate phenotyping of neuroinflammatory processes to refine PRS.

Related Concept Videos